Clinical Trials Browser

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04696731 2025-09-25

TRAVERSE

Phase 1 Active not recruiting

120 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

57 enrolled

GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

6 enrolled

BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06480565 2025-08-15

A Phase 1/2 Trial of ADI-270 in ccRCC

Phase 1/2 Active not recruiting

60 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05665062 2025-04-06

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Phase 1 Active not recruiting

36 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06093841 2025-02-11

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

Phase 2 Active not recruiting

46 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04623944 2024-12-27

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Phase 1 Active not recruiting

61 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04613557 2023-08-31

IMMUNICY-1

Phase 1 Active not recruiting

18 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT04093596 2023-08-14

UNIVERSAL

Phase 1 Active not recruiting

132 enrolled

Plasma cell

Multiple Myeloma

NCT04268706 2023-04-05

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

Phase 2 Active not recruiting

97 enrolled

Lymphoid

Hodgkin Disease

Clinical Trials

IGNYTE-ESO

CARTITUDE-5

aMMbition

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

FT819 in Subjects With B-cell Malignancies

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

KarMMa-9

TUNINTIL-2

ALPHA2

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

JKART-1

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

TRANSCEND FL

ZUMA-22

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

TRAVERSE

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

A Phase 1/2 Trial of ADI-270 in ccRCC

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

IMMUNICY-1

UNIVERSAL

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)